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The sixth Osteoarthritis Research Society International (OARSI) Workshop on Imaging in Osteoarthritis
combined with the third osteoarthritis (OA) Biomarkers Workshop is the ﬁrst to bring together the
imaging and molecular biomarker communities to focus on clinical validation and qualiﬁcation of OA
biomarkers. The workshop was held in Hilton Head, SC, USA, from June 12e14, 2012; 138 attendees
participated, including representatives from academia, pharmaceutical and magnetic resonance imaging
(MRI) industries, Food and Drug Administration (FDA), and National Institutes of Health (NIH). Pre-
sentations and discussions raised awareness, consolidated knowledge, and identiﬁed strategies to
overcome challenges for the development and application of imaging and biochemical biomarkers in OA
research studies and clinical trials.
Conclusion: The OA research communities need to work alongside regulatory agencies across the world,
to qualify and validate new chemical and imaging biomarkers for future research and clinical trials.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Magnetic resonance imaging (MRI) of knee joints has contrib-
uted signiﬁcantly to the change in perception of osteoarthritis (OA)
fromwear and tear disease limited to radiographic changes in bone
and loss of joint space related to cartilage, to a multi-tissue, whole
organ, complex disease with many phenotypes1. Aging, obesity,
injuries, and an adverse mechanical environment from joint
malalignment, can all contribute to OA incidence and progression.
The disease may also proceed via different metabolic pathways
inﬂuenced by race, genetics, and gender.
OA is a symptomatic disease associated with characteristic
changes in synovial tissue structures. Imaging modalities should
reﬂect this complex phenotype. Although, MRI is a holistic struc-
tural assessmentmodality that providesmeasures that are themost: D.J. Hunter, Rheumatology
NSW 2065, Australia. Tel: 61-
Hunter).
s Research Society International. Pdirect and valid measure of joint status, and the most responsive
measure of disease progression1, the United States Food and Drug
Administration (FDA) and the European Medicines Agency (EMA)
have yet to accept MRI as an imaging endpoint for OA in clinical
trials. Currently, the quantitative measurement of radiography-
based joint space width (JSW) is the only accepted imaging
endpoint in disease modiﬁcation efﬁcacy OA trials. Development of
disease-modifying therapy has been slowed because radiography
has limited capacity to detect clinically meaningful changes in joint
morphology that accompany disease progression.
The utility of any disease-related biomarker is a function of how
well the marker links disease biology and pathology with clinical
outcomes. Pain, which along with JSW is a common endpoint in OA
clinical trials, appears to at least partly derive from joint tissue al-
terations (including synovitis, effusion, meniscal pathology, and
bone marrow lesions (BML)) but associations are generally mod-
erate. Not only do these changes go undetected on conventional
radiographs, but pain often antedates radiographic manifestationsublished by Elsevier Ltd. All rights reserved.
Fig. 1. The natural history of OA and the purported roles of biomarkers during the disease process. Original attributed to V Kraus (originally presented at Osteoarthritis Research
Society International (OARSI) Congress 2009: Kraus, VB. 2009. Clinical perspective on the role of biomarkers and the diagnosis and monitoring of OA. Osteoarthritis Cartilage Sept 17
(Suppl 1): S1.) can also be found in5.
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related pain are dynamic. Such variation in disease progression
requires biomarkers that can reﬂect morphological and patholog-
ical changes in joints, beginning in the earliest stages of OA
development and progression and throughout the course of disease
(see Fig. 1). For example, biochemical markers may reﬂect ultra-
structural changes in joint tissue metabolism very early in the
disease process prior to any apparent change in imaging appear-
ance on either radiographs or MRI. Similarly, short-term (weeks/
months) variation in symptoms is unlikely to be reﬂected in poorly
responsive endpoints such as radiographs.
The OA biomarker community has been addressing these and
other issues in a series of workshops2. Most recently, the OARSI
Biomarkers Workshop III e Imaging Biomarker Validation and
Quantiﬁcation organized in conjunction with the sixth Interna-
tional Workshop on Osteoarthritis Imaging, was held July 12e14 on
Hilton Head Island, South Carolina. More than 138 scientists from
academia, the government, and the private sector convened for the
event.
Research presented at the 3-day meeting highlighted progress
in the ﬁeld to validate MRI as a biomarker with prognostic and/or
diagnostic capabilities.
Meeting participants endorsed a plan to facilitate the use of MRI
as an endpoint in large-scale, multi-center interventional clinical
trials with extended follow-up lasting 1 and 2 years, to ascertain the
efﬁcacy and safety of different interventions using MRI-based mea-
sures as a biomarker of efﬁcacy. In discussing the population on
which to base such trials, participants agreed that such a study
should, in one instance, focus on recently injured joints; this study
paradigm facilitates deﬁning a pathway to OA development and
progression because the inciting event and time can be clearly
identiﬁed (a summary of issues under discussion can be found in
Table I).Meeting participants also emphasized that such trials should
utilize imaging technology that could detect differences in the
morphological and compositionalmakeup of an injured joint; detect
differences between the injured and uninjured joint; and monitor
changes in morphological and compositional makeup over time.
Identifying the appropriate imaging modality and parameters
will be critical for ensuring responsive, reproducible and reliableoutcomes. OA typically progresses very slowly so that the disease
can remain at the same structural and clinical level of severity for
many years. Without accurate MRI technology, a BML can be
confused with a contusion or subchondral insufﬁciency fracture,
and what looks like a meniscal tear or cartilage lesions can simply
be an artifact.
An MRI protocol that can assess cartilage quality (e.g., matrix
composition) along with morphology and shape measures may
help distinguish pathology from normal reparative processes (e.g.,
increase in cartilage thickness seen after Anterior Cruciate Liga-
ment (ACL) injury could be pathological swelling or adaptive hy-
pertrophy)3. Imaging modalities that rely on intravenous contrast
administration, which would be useful in assessing synovitis or
cartilage proteoglycan (dGEMRIC), may be difﬁcult to use in the
current clinical trials and epidemiological studies since they add
complexity to the study design and prolong the procedure time;
contrast injection necessitates ascertaining adequate renal function
prior to injection in order to avoid the very rare contrast medium-
induced nephropathy, and entails a waiting period prior to image
acquisition.
Some of the main drivers in MRI research have been a pursuit of
improved metrics for OA trials and their acceptance by regulatory
agencies. Although quantitative measurement of cartilage thick-
ness on MRI may have high validity, carrying it forward for trials
and clinical use depends on a response from the FDA and the EMA
(amongst other world-wide regulatory authorities). In 2010, OARSI
submitted an analysis to the FDA in which the use of MRI in oste-
oarthritic joints was detailed. The FDA is actively working to
address recommendations necessary to approveMRI parameters as
endpoints in clinical trials and this may be facilitated by a formal
request for biomarker qualiﬁcation.
In the opinion of some of the meeting attendees, the imaging
biomarkers that may be best suited for quantitative measurement
of cartilage composition on MRI assessed are T2 and potentially
T1rho. Both T2 and T1rho can be implemented and assessed using a
software package that could be purchased and standardized across
sites4. However, there are challenges regarding the reproducibility
of T2 and T1rho, and thus these modalities will need to be further
standardized before implementation across machines and sites.
Table I
Designing the Optimal Trials for Understanding OA. Discussion and Future Directions
Discussion points Suggestions
Determine imaging modalities for longitudinal multi-center injury trials Use T2 as basis assessment of joint morphology and then T1rho as
background if this modality can be standardized
Establish standard measurement parameters on imaging (a core-set) For example of cartilage composition, cartilage lesions and cartilage
thickness, shape measures need to be collected to determine effect
and which best predicts long-term clinical outcome
Determine best strategy for regulatory bodies to generate different guidance
criteria for different phases of clinical trial intervention
Include MRI with all the other endpoints in early phase trials (especially
Phase 2), and then determine if you can use it later as a primary endpoint
based on the study
Modify requirement for 30e50% reduction in JSW as a threshold for evidence
of successful structural modiﬁcation as no single drug will impact readily
this parameter
Identify which structural changes are most speciﬁcally associated with
clinical endpoints in (knee) OA, and hence need to be treated
Reach a consensus on standardized clinical endpoint so studies are easier
to compare
Explore utility of virtual total joint replacement (TJR) as a potential endpoint
in future clinical trials
Determine histopathological relationship among structural changes to
cartilage and subchondral bone and ‘soft’ tissues of the articular organ
that can be seen on MRI (Joint tissue e MRI structure correlation)
Match treatable pathology with appropriate imaging methodology
Monitor patients for damage in other joints especially when treated by
highly effective analgesics; any damage needs to be detected early
Some suggested methods of determining risk include asking patients about
pain levels; radiographic screening; joint-speciﬁc biochemical markers
Determine whether quantitative MRI, either morphometric, compositional
or semi-quantitative as an endpoint, is a suitable method to be used in
cartilage repair trials and for long-term follow-up
Establish imaging criteria that will label cartilage repair procedures
successful from a radiological and histological standpoint
Need to measure local changes in collagen/GAG and quantitative MRI for
morphology suitability but success of the intervention is determined by
the long-term outcome for the whole joint
MRI (as opposed to arthroscopy) may not be the most suitable outcome
for assessing the boundary between native and repaired cartilage
Be mindful of what one considers successful, as it depends on the
patients’ expectations
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will be used in conjunction with biochemical measures. Toward
that end, OARSI, as part of an initiative with the Foundation of
National Institutes of Health (NIH), has initiated a study using
Osteoarthritis Initiative samples to generate data on 12 urine and
serum OA biomarkers related to cartilage and bone turnover.
Although there’s still a need for more speciﬁc validation regarding
origin, these biochemical measures will be correlated with imaging
measures (or outcomes). Urine sampling is not invasive and is
particularly valuable for collagen biomarkers; but biomarker levels
need to be normalized to urine creatinine to account for the varying
hydration states of the individuals. This initiative will provide the
opportunity to compare a large cadre of imaging and biochemical
markers and to evaluate the potential synergy for these different
types of markers singly, and in combination, to reﬂect disease
status and progression.
The joint itself can be viewed as a “test tube,” with the synovial
ﬂuid providing access to proximal information regarding joint tis-
sue metabolites that can be correlated with imaging or histological
outcomes. Disadvantages to synovial ﬂuid sampling are several,
including: discomfort to the patient, dislike of the procedure by
practitioners, requirement for ancillary imaging (ultrasound or
computed tomography) for sampling of some joints (such as the
hip) and short half-life of some biomarkers in the joint (e.g., the
brief half-life of hyaluronic acid in the joint suggests that the con-
centration of hyaluronic acid changes over minutes). Although
there are disadvantages to sampling synovial ﬂuid, in a research
setting it can provide the most proximal quantitative data through
biomarker analyses of the disease process and thereby can be
invaluable for providing biological insights in the disease.
Biochemical biomarkers may also help categorize who is at risk
and who may beneﬁt from screening for OA by helping detect
signal changes linked to OA. Recognizing those patients who will
progress rapidly will prove critical in the effort to accurately stage
the disease and thus identify people most at risk and most likely to
beneﬁt from therapeutic intervention.
There is a critical need for imaging methods to evaluate Disease
Modifying Osteoarthritis Drug (DMOAD) activity in a reasonabletimeframe, with reasonable sample size, at a reasonable cost.
Setting a framework to evaluate OA biomarkers that include po-
tential for surrogacy as a major emphasis in modiﬁable disease
pathways affecting patient outcomes will identify and advance
biomarkers with the greatest promise.
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